Antibodies News and Research

RSS

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

A new study in health care workers led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation and the Hospital Clínic of Barcelona, shows that IgA and IgM antibodies to SARS-CoV-2 decay quickly, while IgG antibody levels are maintained for at least three months after infection.

23 Nov 2020

Study suggests neutralizing SARS-CoV-2 antibodies offer protection against reinfection

A new study published in November 2020 on the preprint server medRxiv* indicates that the chances of symptomatic infection are indeed much lower among the population with antibodies to the virus.

22 Nov 2020

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

In a recent study published in the preprint server bioRxiv, researchers from the Grifols Bioscience Research Group reported on the collection of convalescent plasma and production of anti-SARS-CoV-2 hyperimmune globulin for use in clinical research.

22 Nov 2020

Research reveals T-cell abnormalities in severe COVID-19 cases

There is an idea within the coronavirus research field that there is some kind of T cell abnormality in critically ill COVID-19 patients, but specific details have not yet been clarified.

20 Nov 2020

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body - a process called metastasis - and developed a potential way to stop it.

20 Nov 2020

Scientists explain potential reasons for SARS-CoV-2 re-infection

A study, which was published in the journal New Microbes and New Infections, focused on the possible reasons for SARS-CoV-2 reinfection.

20 Nov 2020

MMR vaccine could protect against COVID-19

The number of reported global infections of SARS-CoV-2 stands at 56.88 million as of 19 November 2020, and this number continues to rise.

20 Nov 2020

Lonza provides expansive selection of high-resolution HLA-typed primary cells to boost drug development

Lonza has announced that it now provides an expansive selection of high-resolution Human Leukocyte Antigen (HLA)-typed primary cells spanning all major cell and tissue types.

From Lonza 20 Nov 2020

Scientists develop a new vaccine approach for HIV

Unlike so many other deadly viruses, HIV still lacks a vaccine. The virus--which continues to infect millions around the world--has proven especially tricky to prevent with conventional antibodies, in part because it evolves so rapidly in the body.

20 Nov 2020

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

A genetic modification in the 'coat' of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers.

20 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Antibody combinations may be more effective at preventing, treating COVID-19

Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York.

19 Nov 2020

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

The researchers show that the mice immunized with homotypic or mosaic nanoparticles produced broad binding and neutralizing responses, in contrast to plasma antibodies elicited in humans by SARS-CoV-2 infection. The RBD nanoparticles induced cross-reactive IgG responses in the immunized mice.

19 Nov 2020

Texas Biomed awarded $1 million to evaluate MAb therapeutics for COVID-19

Texas Biomedical Research Institute in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection.

19 Nov 2020

Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally

A recent systematic review and meta-analysis conducted by a team of international scientists reveal low seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the general population.

19 Nov 2020

Antibodies News and Research

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

Study suggests neutralizing SARS-CoV-2 antibodies offer protection against reinfection

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

Research reveals T-cell abnormalities in severe COVID-19 cases

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

Scientists explain potential reasons for SARS-CoV-2 re-infection

MMR vaccine could protect against COVID-19

Lonza provides expansive selection of high-resolution HLA-typed primary cells to boost drug development

Scientists develop a new vaccine approach for HIV

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Antibody combinations may be more effective at preventing, treating COVID-19

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

Texas Biomed awarded $1 million to evaluate MAb therapeutics for COVID-19

Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News